Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Cash Flow: 2015-2024

Historic Net Cash Flow for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $77.2 million.

  • UroGen Pharma's Net Cash Flow rose 97.26% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 689.79%. This contributed to the annual value of $77.2 million for FY2024, which is 95.04% up from last year.
  • Latest data reveals that UroGen Pharma reported Net Cash Flow of $77.2 million as of FY2024, which was up 95.04% from $39.6 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Net Cash Flow peaked at $77.2 million during FY2024, and registered a low of -$8.5 million during FY2021.
  • For the 3-year period, UroGen Pharma's Net Cash Flow averaged around $42.5 million, with its median value being $39.6 million (2023).
  • In the last 5 years, UroGen Pharma's Net Cash Flow tumbled by 319.23% in 2021 and then soared by 272.37% in 2023.
  • Over the past 5 years, UroGen Pharma's Net Cash Flow (Yearly) stood at $3.9 million in 2020, then tumbled by 319.23% to -$8.5 million in 2021, then skyrocketed by 225.06% to $10.6 million in 2022, then spiked by 272.37% to $39.6 million in 2023, then skyrocketed by 95.04% to $77.2 million in 2024.